NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
FOR IMMEDIATE RELEASE
21 April 2026
Admission of New British Land Shares
In connection with the recommended cash and share offer by The British Land Company plc ("British Land") for the entire issued and to be issued share capital of Life Science REIT plc, British Land is pleased to confirm that 24,500,000 new ordinary shares with a nominal value of 25 pence each and each with one voting right (the "New British Land Shares") were admitted to trading on the Main Market of the London Stock Exchange, with effect from 8.00 a.m. today, 21 April 2026. The New British Land Shares are fully fungible with the existing Ordinary Shares.
Following the admission of the New British Land Shares, British Land's total number of Ordinary Shares in issue shall be 1,035,669,895 Ordinary Shares. British Land holds 11,266,245 ordinary shares in treasury. Accordingly, the total number of voting rights in British Land is 1,024,403,650. British Land's ordinary shares are admitted to trading on the London Stock Exchange and their International Securities Identification Number ("ISIN") code is GB0001367019.
The above figure of 1,024,403,650 may be used by shareholders and others for the calculations by which they will determine if they are required to notify British Land and the FCA of the percentage of voting rights they hold, or a change in this percentage, under the FCA's Disclosure Guidance and Transparency Rules.
British Land has a sponsored American Depositary Receipts ("ADR") programme for which Bank of New York Mellon acts as the sponsored depositary bank. One ADR represents one ordinary share of British Land. The ADRs trade on the US OTC market under the symbol BTLCY. The CUSIP number is 110828100 and the ISIN is US1108281007.
New British Land Shares held in uncertificated form are expected to be credited to CREST accounts on or as soon as possible after 8.00 a.m. on 21 April 2026 (but no later than 4 May 2026) and British Land will procure the despatch of share certificates in respect of New British Land Shares held in certificated form by no later than 4 May 2026.
British Land's LEI is RV5B68J2GV3QGMRPW209.
Enquiries:
British Land
Jonty McNuff (Investors) +44 (0)7931 684 272
Harriet Scott (Media) +44 (0)7977 572 190
Charlotte Whitley (Media) +44 (0)7887 802 535
Notes regarding New British Land Shares
The New British Land Shares have not been and will not be registered under the US Securities Act, or under the relevant securities laws of any state, territory or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration under the US Securities Act, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. It is expected that the New British Land Shares will be issued in reliance upon the exemption from the registration requirements of the US Securities Act provided by Section 3(a)(10) thereof. For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Life Science REIT advised the Court that its sanctioning of the Scheme will be relied on by British Land for the purposes of a Section 3(a)(10) exemption following a hearing on the fairness of the Scheme to Life Science REIT Shareholders.
The New British Land Shares to be issued pursuant to the Scheme have not been and will not be registered under the relevant securities laws of Japan and the relevant clearances have not been, and will not be, obtained from the securities commission of any province of Canada. No prospectus in relation to the New British Land Shares has been, or will be, lodged with, or registered by, the Australian Securities and Investments Commission.
Accordingly, the New British Land Shares are not being, and may not be, offered, sold, resold, delivered or distributed, directly or indirectly in or into a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of relevant laws of, or require registration thereof in, such jurisdiction (except pursuant to an exemption, if available, from any applicable registration requirements or otherwise in compliance with all applicable laws).